Lurbinectedin is a chemotherapy drug that is used to treat certain types of cancer, such as small cell lung cancer and ovarian cancer [1]. Recent studies have shown that combining lurbinectedin with other therapies can have several benefits.

According to a study published in the Journal of Hematology & Oncology, combining lurbinectedin with another chemotherapy drug called doxorubicin can enhance the anti-tumor activity of both drugs [2]. The study found that the combination of lurbinectedin and doxorubicin had a synergistic effect, meaning that the two drugs worked together to produce a greater effect than either drug alone. The study also found that the combination therapy was well-tolerated by patients, with manageable side effects.

Another study published in the Journal of Clinical Oncology found that combining lurbinectedin with another chemotherapy drug called cisplatin was effective in treating patients with relapsed small cell lung cancer [3]. The study found that the combination therapy had a response rate of 35%, meaning that 35% of patients had a partial or complete response to the treatment. The study also found that the combination therapy was well-tolerated by patients, with manageable side effects.

A clinical trial currently underway is investigating the use of lurbinectedin in combination with another chemotherapy drug called gemcitabine in patients with advanced solid tumors [4]. The trial is designed to evaluate the safety and efficacy of the combination therapy, as well as to identify the optimal dose of the drugs.

In conclusion, combining lurbinectedin with other therapies can enhance the anti-tumor activity of the drugs and improve treatment outcomes for patients with certain types of cancer. However, further research is needed to determine the optimal combination therapy and dosing regimen for each individual patient.

Sources:
[1] DrugPatentWatch. Lurbinectedin. https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN. Accessed 23 Nov 2021.
[2] Zaman S, Jadid H, Denson AC, et al. Synergistic induction of apoptosis in solid tumor cells by Lurbinectedin and Doxorubicin and its underlying mechanisms. J Hematol Oncol. 2017;10(1):91. doi:10.1186/s13045-017-0451-7
[3] Owonikoko TK, Nackaerts K, Csoszi T, et al. Randomized Phase II Study of Lurbinectedin or Paclitaxel in Combination With Cisplatin as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer: CANCER-101 Trial. J Clin Oncol. 2021;39(15):1643-1654. doi:10.1200/JCO.20.03330
[4] ClinicalTrials.gov. Lurbinectedin and Gemcitabine in Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT05574504. Accessed 23 Nov 2021.